Results 231 to 240 of about 7,712,957 (388)

MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancer

Molecular Oncology, EarlyView.
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu, Ning Ding, Xiaobo Xu, Yedan Chen, Yong Zhang, Jingwen Liu, Jiebai Zhou, Hairong Bao, Donghui Zhang, Yijun Song, Yang Shao, Yuanlin Song   +11 more
wiley   +1 more source

Clinical Features and Patient-Reported Outcomes in a Cohort of Patients with Sjögren's Disease. [PDF]

J Clin Med
Izzetti R, Cinquini C, Fulvio G, Nisi M, Baldini C, Barone A.   +5 more
europepmc   +1 more source

MS4 THE IMPACT OF HEALTH CARE ATTITUDES ON PATIENT REPORTED OUTCOMES (PRO'S)

, 2003
SC Bolge, K. Annunziata, JA Donohue
openalex   +1 more source

Chemoresistome mapping in individual breast cancer patients unravels diversity in dynamic transcriptional adaptation

Molecular Oncology, EarlyView.
This study used longitudinal transcriptomics and gene‐pattern classification to uncover patient‐specific mechanisms of chemotherapy resistance in breast cancer. Findings reveal preexisting drug‐tolerant states in primary tumors and diverse gene rewiring patterns across patients, converging on a few dysregulated functional modules. Despite receiving the
Maya Dadiani, Gilgi Friedlander, Gili Perry, Nora Balint‐Lahat, Shlomit Gilad, Dana Morzaev‐Sulzbach, Anjana Shenoy, Noa Bossel Ben‐Moshe, Anya Pavlovsky, Rinat Bernstein‐Molho, Eytan Domany, Iris Barshack, Tamar Geiger, Bella Kaufman, Einav Nili Gal‐Yam   +14 more
wiley   +1 more source

Patient reported outcomes in the FDA approved drugs for systemic rheumatic diseases (2013-2024). [PDF]

Health Qual Life Outcomes
Xie Y, Liu Y, Qin Y, Yin G, Chen X, Xie Q.   +5 more
europepmc   +1 more source

PHP37 USING PATIENT REPORTED OUTCOMES (PRO) DATA TO SEGMENT HEALTH CARE CONSUMERS AND UNCOVER THEIR RECEPTIVENESS TO PHARMACEUTICAL ADVERTISING

, 2003
Mary Edmondson, Diana D. McDonnell
openalex   +1 more source

Outcome in children with purpura fulminans: Report on 16 patients [PDF]

, 2005
Aytemiz Gürgey, Selin Aytaç, G Kanra, G Seçmeer, Mehmet Ceyhan, Çiğdem Altay   +5 more
openalex   +1 more source

Tonic signaling of the B‐cell antigen‐specific receptor is a common functional hallmark in chronic lymphocytic leukemia cell phosphoproteomes at early disease stages

Molecular Oncology, EarlyView.
B‐cell chronic lymphocytic leukemia (B‐CLL) and monoclonal B‐cell lymphocytosis (MBL) show altered proteomes and phosphoproteomes, analyzed using mass spectrometry, protein microarrays, and western blotting. Identifying 2970 proteins and 316 phosphoproteins, including 55 novel phosphopeptides, we reveal BCR and NF‐kβ/STAT3 signaling in disease ...
Paula Díez, Pablo Juanes‐Velasco, Marina L. García‐Vaquero, Conrad Droste, Alicia Landeira‐Viñuela, Miguel Alcoceba, Helena Fidalgo‐Gómez, Sara Misiego‐Herrero, Almudena Navarro‐Bailón, Mónica Baile, José M. Bastida, Jose Manuel Sanchez‐Santos, Rafael Góngora, Julia Almeida, Marcos Gonzalez‐Diaz, Alberto Orfao, Javier De Las Rivas, Manuel Fuentes   +17 more
wiley   +1 more source

Patient-reported outcomes with subcutaneous immunoglobulin in secondary immunodeficiency. [PDF]

Front Immunol
Cowan J, Na IK, Gladiator A, Kamieniak M, Mustafa SS.   +4 more
europepmc   +1 more source

PCN29: DEVELOPING A MEASUREMENT STRATEGY FOR PATIENT-REPORTED OUTCOMES: FINDINGS FROM THE NCI'S CANCER OUTCOMES MEASUREMENT WORKING GROUP

, 2003
C. Snyder, Justina Lipscomb, CC Gotay
openalex   +1 more source